← Back to Search

Monoclonal Antibodies

Rocatinlimab for Prurigo Nodularis

Phase 3
Recruiting
Research Sponsored by Amgen
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age ≥ 18 years (or any legal adult age within the country if it is older than 18 years)
Has ≥ 20 prurigo nodularis nodules in total with bilateral distribution on both legs and /or arms and /or trunk
Must not have
Prurigo nodularis secondary to neurologic or psychiatric medical conditions
Treatment with any systemic biologic immunosuppressive or systemic biologic immunomodulatory therapy for prurigo nodularis or any other autoimmune, inflammatory, or allergic disease within 12 weeks or 5 half-lives, whichever is longer, prior to day 1 prerandomization
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to approximately week 68
Awards & highlights

Summary

"This trial will assess if roctatinlimab is better than a placebo in reducing itching and improving overall clinical assessment after 24 weeks, as reported by the patients."

Who is the study for?
This trial is for individuals with skin conditions like Atopic Dermatitis and Prurigo Nodularis, who experience severe itching. Participants should be willing to receive injections and not have any health issues that could interfere with the study or pose a risk when taking the trial medication.
What is being tested?
The study aims to test Rocatinlimab's effectiveness against a placebo in reducing itchiness at week 24, using patient-reported outcomes and clinical assessments. It's a phase 3 trial where participants won't know if they're getting the real medicine or a dummy injection (double-blind).
What are the potential side effects?
While specific side effects of Rocatinlimab are not listed here, common ones may include reactions at the injection site, headaches, fatigue, or flu-like symptoms. Placebo injections usually have no active ingredients but can cause similar minor reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am at least 18 years old or the legal adult age in my country.
Select...
I have 20 or more itchy bumps on both sides of my legs, arms, or trunk.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have itchy bumps on my skin due to a nerve or mental health condition.
Select...
I haven't taken any immune system affecting drugs for my condition in the last 12 weeks or 5 half-lives, whichever is longer.
Select...
I have itchy bumps on my skin caused by medication.
Select...
I have not received any live vaccines in the last 12 weeks.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to approximately week 68
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to approximately week 68 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Secondary outcome measures
Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)

Trial Design

4Treatment groups
Experimental Treatment
Group I: Arm D: Open-labelExperimental Treatment1 Intervention
Participants will receive open-label rocatinlimab dose 1 SC during Treatment Period B.
Group II: Arm C: Blinded TreatmentExperimental Treatment1 Intervention
Participants will receive matching placebo SC during Treatment Period A and B.
Group III: Arm B: Blinded TreatmentExperimental Treatment1 Intervention
Participants will receive rocatinlimab dose 2 SC during Treatment Period A and B.
Group IV: Arm A: Blinded TreatmentExperimental Treatment1 Intervention
Participants will receive rocatinlimab dose 1 subcutaneously (SC) during Treatment Period A and B.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Rocatinlimab
2024
Completed Phase 3
~750
Placebo
1995
Completed Phase 3
~2670

Find a Location

Who is running the clinical trial?

AmgenLead Sponsor
1,420 Previous Clinical Trials
1,382,490 Total Patients Enrolled
MDStudy DirectorAmgen
961 Previous Clinical Trials
928,405 Total Patients Enrolled
~307 spots leftby Feb 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top